CT Volume Measurement of Hepatocellular Carcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
The aim of this study is to evaluate the role of CT volumetric measurement in assessing treatment response of hepatocellular carcinoma (HCC) following trans arterial chemoembolization (TACE) or microwave ablation (MWA)
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients (≥18 years) with a confirmed diagnosis of HCC based on AASLD or EASL criteria.
Patients deemed unresectable by the multidisciplinary tumor board.
Patients scheduled for TACE as the primary locoregional therapy.
Preserved liver function (Child-Pugh class A or B).
Disqualifiers
Patients with extrahepatic metastases or portal vein thrombosis.
Patients with contraindications to iodinated contrast or TACE.
Patients with severe comorbid illness that precludes participation.
Patients refuse to provide informed consent.
Trial population
All patients admitted to Assiut University Hospital, Egypt during the period of the study and fulfil the inclusion criteria
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Ct
DeviceCt volume measurement of HCC after TACE or MWA
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Ct volume measurent of hepatocellular carcinoma after Transarterial chemoembolization or microwave ablation
At enrollment, all patients will undergo a comprehensive clinical assessment, including full medical history with emphasis on risk factors for hepatocellular carcinoma triphasic CT scan of the liver, which will serve as the reference for tumor volume (by cm3 or cc), number, and distribution prior to TACE or MWA.
Time frame
BaselineLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: